Tevis Investment Management Acquires 29,390 Shares of Novo Nordisk A/S $NVO

Tevis Investment Management raised its stake in Novo Nordisk A/S (NYSE:NVO) by 65.7% in the 1st quarter, HoldingsChannel reports. The firm owned 74,090 shares of the company’s stock after acquiring an additional 29,390 shares during the quarter. Novo Nordisk A/S makes up 1.6% of Tevis Investment Management’s portfolio, making the stock its 19th biggest position. Tevis Investment Management’s holdings in Novo Nordisk A/S were worth $2,813,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in NVO. Loomis Sayles & Co. L P increased its position in Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after buying an additional 969,916 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after acquiring an additional 717,719 shares in the last quarter. Morgan Stanley boosted its holdings in Novo Nordisk A/S by 3.5% in the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after acquiring an additional 428,660 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after acquiring an additional 4,836,285 shares during the period. Finally, State Street Corp increased its holdings in shares of Novo Nordisk A/S by 1.0% during the third quarter. State Street Corp now owns 6,106,836 shares of the company’s stock valued at $340,125,000 after acquiring an additional 59,153 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.0%

Shares of NYSE:NVO opened at $49.49 on Monday. The business’s 50 day moving average is $45.57 and its 200 day moving average is $45.86. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $71.79. The stock has a market cap of $220.96 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 4.51 and a beta of 0.77. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s Wegovy access continues to expand, and a recent U.K. approval has added to optimism around demand for its GLP-1 franchise, supporting the stock’s recent rebound. Article Title
• Positive Sentiment: The company launched Awiqli, the world’s first once-weekly basal insulin, in India, a move that could strengthen Novo Nordisk’s diabetes footprint in a large and fast-growing market. Article Title
• Positive Sentiment: Analysts and commentators continue to argue that the stock still has a long-term bull case, with some saying the decline from highs has made the valuation more attractive relative to the company’s growth prospects. Article Title
• Neutral Sentiment: Several articles note that investors are simply watching Novo Nordisk more closely, suggesting heightened interest rather than a single new fundamental catalyst. Article Title
• Neutral Sentiment: Coverage around a Wegovy label update and broader GLP-1 enthusiasm is keeping the name in focus, but the market appears to be balancing this against the risk that competition and earnings pressure could limit upside. Article Title
• Negative Sentiment: Recent commentary also highlights rising competition in the obesity and diabetes drug markets, which could pressure Novo Nordisk’s growth and margins over time. Article Title
• Negative Sentiment: One recent market note said NVO has been slipping relative to the broader market, reflecting some near-term profit taking after the stock’s strong run. Article Title

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NVO. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target for the company. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Finally, Wolfe Research started coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. Five equities research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.